FDA And Industry Set Out GDUFA III Priorities
Focusing Initially On First-Cycle Approvals And Priority Assessment Improvements
Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
You may also be interested in...
While the new guidance on ANDA label revision “provides clear expectations” from the FDA, the revised guidance on amendments to tentatively approved ANDAs is yet to answer questions from AAM.
Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.